ERDERA will return to the World Orphan Drug Congress Europe with a booth and an interactive pre-conference workshop examining where artificial intelligence can support rare disease research and therapeutic development, and where human expertise remains essential.

Despite the clear benefits of comprehensive newborn screening, implementation across Europe remains strikingly inconsistent. While some countries screen for more than 30 conditions, others test for fewer than 10, creating significant health inequities.

ERDERA

Feedback is open until 14 July 2026, giving stakeholders an early opportunity to comment during the preparation of a likely legislative proposal for a Council regulation.

Boston, 9–11 June 2026: ERDERA's Scientific Coordinator joined the World Orphan Drug Congress USA to set out how stronger clinical research networks can make rare disease trials more feasible across s...

30 million people in Europe live with a rare disease. Yet most still lack a diagnosis or treatment. So what is ERDERA doing about it?

Key takeaways from ERDERA’s first in-person meeting uniting countries on rare disease research.

From 25–28 May in Barcelona, the EURORDIS-led Open Academy x ERDERA Schools will bring patient advocates and early-career researchers together for four days of rare disease training, exchange and peer learning.